OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

About this update from Ose Immunotherapeutics Sa

[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development ","length":100,"tagName":"p"},{"type":"text","content":"Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment","length":128,"tagName":"p"},{"type":"text","content":"NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.","length":322,"tagName":"p"},{"type":"text","content":"Under the revised agreement, OSE Immunotherapeutics regains control of the early-stage development of the ABBV-230, while AbbVie maintains its rights to control future development and commercialization following successful completion of Phase 1. The revised approach reflects both parties’ continued enthusiasm for the potential of ABBV-230 and aligns development responsibilities with each company’s core strengths.","length":416,"tagName":"p"},{"type":"text","content":"Highlights of the Amended Agreement ","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"OSE Immunotherapeutics to Lead Early Development: OSE Immunotherapeutics will assume responsibility for the preclinical and Phase 1 development of ABBV-230, drawing on its deep immunology expertise. These activities will be fully financed by OSE Immunotherapeutics, contingent upon securing adequate funding, at its sole discretion.","length":332,"tagName":"p"}]},{"val":[{"type":"text","content":"AbbVie Retains Future Rights: AbbVie remains the exclusive licensee and retains its rights to develop and commercialize fo...

More updates from Ose Immunotherapeutics Sa